RFK Jr. Takes Aim at Psychiatric Drug Overprescribing — But His Solutions Raise Alarms

Robert F. Kennedy Jr., the U.S. Secretary of Health and Human Services, unveiled a new federal initiative this week targeting what he calls the “overuse” of psychiatric drugs, particularly selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressants. Speaking at the MAHA Institute Mental Health and Overmedicalization Summit, Kennedy promised a shift toward “prevention, transparency, and a more holistic approach to mental health,” emphasizing patient autonomy and informed consent.

Kennedy’s plan includes encouraging clinicians to “deprescribe” psychiatric medications when appropriate and expanding nonpharmacologic treatments like psychotherapy, exercise, and nutrition. A “Dear Colleague” letter urged providers to rethink medications as just one tool rather than the default solution.

But Kennedy’s approach is fraught with controversy. He has repeatedly claimed SSRIs are more addictive than heroin and linked them to school shootings—assertions widely debunked by medical experts. Tami Benton, president of the American Academy of Child and Adolescent Psychiatry, firmly rejected the comparison, stating, “These medications are not addictive and they’re not at all like heroin.”

Adding to the alarm, Kennedy’s suggestion to send children with mental health or drug issues to work or farm camps has drawn sharp criticism. During his 2024 presidential campaign, he proposed “reparenting” Black children on wellness farms—a notion denounced as racist and harmful by lawmakers including Senator Angela Alsobrooks. Kennedy has since apologized but remains committed to similar ideas.

The American Psychiatric Association also expressed skepticism. CEO Marketa Wills acknowledged overprescribing exists but cautioned against oversimplifying mental health care challenges, noting that many still lack access to needed treatment.

Kennedy’s personal history with heroin addiction colors his rhetoric. At the summit, he described enduring withdrawal “more than 100 times,” using it to justify his tough stance on psychiatric drugs. Yet experts warn that conflating addiction with prescribed antidepressant use misleads patients and risks undermining effective care.

While Kennedy’s stated goal—to reduce unnecessary psychiatric drug use—is laudable, his methods raise serious questions. Advocates worry that punitive or misguided policies could worsen mental health outcomes, especially for vulnerable youth, rather than improve them.

As the federal government steps into the fraught terrain of mental health treatment reform, it must tread carefully. Patients deserve evidence-based, compassionate care—not alarmist rhetoric and controversial experiments masquerading as solutions. We will be watching closely to see whether Kennedy’s promises translate into real progress or deepen the crisis.